MedTrace Logo

Adjuvant Radiotherapy for Patients With Esophageal Squamous Cell Carcinoma After R0 Resection

NCT05460403 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 3591

Last updated 2022-07-15

No results posted yet for this study

Summary

This retrospective study is exploring the treatment effect and toxicity of adjuvant radiotherapy in patients diagnosed with esophageal squamous cell carcinoma after R0 resection.

Conditions

  • Esophageal Cancer

Interventions

RADIATION

Adjuvant Radiotherapy

Patients undergo radiotherapy once daily 5 days a week for an average of 5.5 weeks within 12 weeks after surgery in the absence of disease progression or unacceptable toxicity.

Sponsors & Collaborators

  • Fujian Cancer Hospital

    collaborator OTHER_GOV

  • Chinese Academy of Medical Sciences

    lead OTHER

Principal Investigators

  • Zefen Xiao, MD · Department of Radiation Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Science

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-23
Primary Completion
2023-07-02
Completion
2023-08-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05460403 on ClinicalTrials.gov